Evidence map›Paper›PMID 40524205›Full record

ArticleThyroid research2025

The utility of

Eline C Jager, James McNeil, Alexander J Papachristos, Mark Sywak, Stan B Sidhu, Rhonda Siddall, Jeremy Hoang, Geoffrey P Schembri, Venessa H M Tsang, Ayanthi Wijewardene and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thyroid research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Eline C JagerDepartment of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia. e.c.jager@umcg.nl.
James McNeilDepartment of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.
Alexander J PapachristosFaculty of Medicine and Health, University of Sydney, Sydney, Australia.
Mark SywakFaculty of Medicine and Health, University of Sydney, Sydney, Australia.
Stan B SidhuFaculty of Medicine and Health, University of Sydney, Sydney, Australia.
Rhonda SiddallDepartment of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.
Jeremy HoangFaculty of Medicine and Health, University of Sydney, Sydney, Australia.
Geoffrey P SchembriDepartment of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia.
Venessa H M TsangDepartment of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.
Ayanthi WijewardeneDepartment of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.
Lyndal TaconDepartment of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.
Bruce RobinsonDepartment of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.
Roderick J Clifton-BlighDepartment of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.
Martyn BullockFaculty of Medicine and Health, University of Sydney, Sydney, Australia.
Adrienne H BrouwersDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Thera P LinksDepartment of Internal Medicine, Division of Endocrinology, University Medical Centre Groningen, Groningen, The Netherlands.
Schelto KruijffDepartment of Surgery, Division of Surgical Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
Anthony R Glover *Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Matti L Gild *Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia. matti.gild@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of patients with advanced medullary thyroid cancer (MTC). However, treatment response heterogeneity leads to challenges in predicting individual favourable response. This study evaluated the correlation between PET metrics on

methodsThis study retrospectively evaluated patients with metastatic MTC who received TKIs at a tertiary care hospital and had prior

resultsIn the 25 patients, mean age at diagnosis was 48 (±15) years; 11 (44%) were female and 21 tumors harbored RET driver alterations. Thirty-six TKI treatments were administered (11 patients received two TKIs sequentially). RECIST response rates (available in 32/36 treatments) included; stable disease in 8/32 (25%), partial response in 23/32 (72%) and complete response in 1/32 (3%) treatments. In total, 30 pre-TKI PET/CTs (24

conclusionsIn a small cohort of MTC patients, MTV and TLA on

Indexed as

Medullary thyroid carcinomaPET/CT imagingResponse predictionTyrosine kinase inhibitors

Identifiers

PMID40524205
PMCPMC12172355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.